As the cost of insulin rises, lawmakers in dozens of states are trying to reduce the burden on diabetics who are struggling to afford their prescriptions.

But the drug industry is pushing back: Pharmaceutical lobbyists have fought some state efforts that would have cut into their profits, an investigation by FairWarning found.